These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1099 related articles for article (PubMed ID: 28189457)
21. mTORC2/AKT/HSF1/HuR constitute a feed-forward loop regulating Rictor expression and tumor growth in glioblastoma. Holmes B; Benavides-Serrato A; Freeman RS; Landon KA; Bashir T; Nishimura RN; Gera J Oncogene; 2018 Feb; 37(6):732-743. PubMed ID: 29059166 [TBL] [Abstract][Full Text] [Related]
22. Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin. Zou Z; Chen J; Yang J; Bai X Curr Cancer Drug Targets; 2016; 16(4):288-304. PubMed ID: 26563881 [TBL] [Abstract][Full Text] [Related]
23. Autoregulation of the mechanistic target of rapamycin (mTOR) complex 2 integrity is controlled by an ATP-dependent mechanism. Chen CH; Kiyan V; Zhylkibayev AA; Kazyken D; Bulgakova O; Page KE; Bersimbaev RI; Spooner E; Sarbassov DD J Biol Chem; 2013 Sep; 288(38):27019-27030. PubMed ID: 23928304 [TBL] [Abstract][Full Text] [Related]
24. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). García-Martínez JM; Alessi DR Biochem J; 2008 Dec; 416(3):375-85. PubMed ID: 18925875 [TBL] [Abstract][Full Text] [Related]
25. Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML. Herschbein L; Liesveld JL Blood Rev; 2018 May; 32(3):235-248. PubMed ID: 29276026 [TBL] [Abstract][Full Text] [Related]
26. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival. Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808 [TBL] [Abstract][Full Text] [Related]
27. Dynamic modelling of the PI3K/MTOR signalling network uncovers biphasic dependence of mTORC1 activity on the mTORC2 subunit SIN1. Ghomlaghi M; Yang G; Shin SY; James DE; Nguyen LK PLoS Comput Biol; 2021 Sep; 17(9):e1008513. PubMed ID: 34529665 [TBL] [Abstract][Full Text] [Related]
28. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. Feldman ME; Apsel B; Uotila A; Loewith R; Knight ZA; Ruggero D; Shokat KM PLoS Biol; 2009 Feb; 7(2):e38. PubMed ID: 19209957 [TBL] [Abstract][Full Text] [Related]
29. Reduced menin expression impairs rapamycin effects as evidenced by an increase in mTORC2 signaling and cell migration. Razmara M; Monazzam A; Skogseid B Cell Commun Signal; 2018 Oct; 16(1):64. PubMed ID: 30285764 [TBL] [Abstract][Full Text] [Related]
30. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2. Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820 [TBL] [Abstract][Full Text] [Related]
31. Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex. Gkountakos A; Pilotto S; Mafficini A; Vicentini C; Simbolo M; Milella M; Tortora G; Scarpa A; Bria E; Corbo V Carcinogenesis; 2018 Jul; 39(8):971-980. PubMed ID: 29955840 [TBL] [Abstract][Full Text] [Related]
32. PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling. Woo SY; Kim DH; Jun CB; Kim YM; Haar EV; Lee SI; Hegg JW; Bandhakavi S; Griffin TJ; Kim DH J Biol Chem; 2007 Aug; 282(35):25604-12. PubMed ID: 17599906 [TBL] [Abstract][Full Text] [Related]
33. Mechanistic Target of Rapamycin Complex 1 (mTORC1) and mTORC2 as Key Signaling Intermediates in Mesenchymal Cell Activation. Walker NM; Belloli EA; Stuckey L; Chan KM; Lin J; Lynch W; Chang A; Mazzoni SM; Fingar DC; Lama VN J Biol Chem; 2016 Mar; 291(12):6262-71. PubMed ID: 26755732 [TBL] [Abstract][Full Text] [Related]
34. mTOR kinase leads to PTEN-loss-induced cellular senescence by phosphorylating p53. Jung SH; Hwang HJ; Kang D; Park HA; Lee HC; Jeong D; Lee K; Park HJ; Ko YG; Lee JS Oncogene; 2019 Mar; 38(10):1639-1650. PubMed ID: 30337688 [TBL] [Abstract][Full Text] [Related]
35. The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206. Wang H; Huang F; Wang J; Wang P; Lv W; Hong L; Li S; Zhou J Cell Cycle; 2015; 14(2):232-42. PubMed ID: 25607647 [TBL] [Abstract][Full Text] [Related]
36. TP53 mutated glioblastoma stem-like cell cultures are sensitive to dual mTORC1/2 inhibition while resistance in TP53 wild type cultures can be overcome by combined inhibition of mTORC1/2 and Bcl-2. Venkatesan S; Hoogstraat M; Caljouw E; Pierson T; Spoor JK; Zeneyedpour L; Dubbink HJ; Dekker LJ; van der Kaaij M; Kloezeman J; Berghauser Pont LM; Besselink NJ; Luider TM; Joore J; Martens JW; Lamfers ML; Sleijfer S; Leenstra S Oncotarget; 2016 Sep; 7(36):58435-58444. PubMed ID: 27533080 [TBL] [Abstract][Full Text] [Related]
37. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). García-Martínez JM; Moran J; Clarke RG; Gray A; Cosulich SC; Chresta CM; Alessi DR Biochem J; 2009 Jun; 421(1):29-42. PubMed ID: 19402821 [TBL] [Abstract][Full Text] [Related]
38. Differential roles and activation of mammalian target of rapamycin complexes 1 and 2 during cell migration in prostate cancer cells. Venugopal SV; Caggia S; Gambrell-Sanders D; Khan SA Prostate; 2020 Apr; 80(5):412-423. PubMed ID: 31995655 [TBL] [Abstract][Full Text] [Related]
39. Sin1 promotes proliferation and invasion of prostate cancer cells by modulating mTORC2-AKT and AR signaling cascades. Huang Y; Feng G; Cai J; Peng Q; Yang Z; Yan C; Yang L; Wang Z Life Sci; 2020 May; 248():117449. PubMed ID: 32088212 [TBL] [Abstract][Full Text] [Related]
40. Selective interference of mTORC1/RAPTOR protects against human disc cellular apoptosis, senescence, and extracellular matrix catabolism with Akt and autophagy induction. Ito M; Yurube T; Kakutani K; Maeno K; Takada T; Terashima Y; Kakiuchi Y; Takeoka Y; Miyazaki S; Kuroda R; Nishida K Osteoarthritis Cartilage; 2017 Dec; 25(12):2134-2146. PubMed ID: 28888905 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]